Data Material
ALK Medical Affairs North America provides the resources found on this website for U.S. healthcare professionals only.
Efficacy and safety of house dust mite sublingual immunotherapy tablet for allergic rhinoconjunctivitis in subjects ≥50 years
Congress MaterialIntroduction
• Allergic rhinitis/conjunctivitis (AR/C) affects individuals of all ages
• Sublingual immunotherapy (SLIT)-tablets are FDA-approved up to
age 65 years for the treatment of AR/C
• Previous analyses of grass and ragweed SLIT-tablet trials indicate
that patients ≥50 years manifest an adequate immunological
response and clinical effect from SLIT-tablet treatment similar to
younger adults